Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its ​rare metabolic disorder drug following acquirer Neurocrine's ‌plans to sharpen focus on the U.S. market.